Navigation Links
WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
Date:4/1/2008

FREMONT, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced the signing of an exclusive distribution agreement for the company's SmartSlide(TM) Micro-Incubation System with IUL Instruments GmbH in Germany. The distributor agreement covers WaferGen's entire family of SmartSlide Micro-Incubation System products. IUL Instruments is a leading distributor of innovative scientific products to researchers in the microbiology, cell biology and biotechnology markets in Germany. IUL Instruments will feature the SmartSlide Micro-Incubation System at Analytica 2008, a leading international conference focused on analytical instrumentation, laboratory technology and biotechnology that is being held April 1-4 in Munich, Germany.

WaferGen's SmartSlide Micro-Incubation System is a first-of-its-kind family of integrated fluidics exchange micro-incubation products that work seamlessly with inverted microscopes. This breakthrough technology is enabling cell biology and stem cell researchers to conduct complex time lapse imaging studies to characterize, differentiate and proliferate cells, as well as grow stem, primary and other difficult to cultivate cells in consistently optimal physiological conditions. These innovative capabilities will allow researchers to pursue cutting-edge research topics that are not addressable with existing technology.

"With the signing of this agreement, WaferGen has established a valuable distribution channel into another key overseas market for our SmartSlide Micro-Incubation System. In addition to our U.S. sales efforts, we now have the relationships in place to successfully deliver the SmartSlide Micro-Incubation System family of products to researchers in the United Kingdom, France, Germany, Australia, Singapore and the Benelux," said Alnoor Shivji, WaferGen's chairman and chief executive officer. "By continuing to broaden our sales and distribution reach, we are making it possible for more and more researchers throughout the world to benefit directly from the critical performance advantages offered by our SmartSlide Micro-Incubation System."

About the SmartSlide(TM) Micro-Incubation System

WaferGen has developed and is currently marketing the SmartSlide Micro-Incubation System, a first-of-its-kind family of integrated fluidics exchange micro-incubation products that work seamlessly with inverted microscopes. This breakthrough technology is enabling cell biology and stem cell researchers to conduct complex time lapse imaging studies to characterize, differentiate and proliferate cells, as well as grow stem, primary and other difficult to cultivate cells in consistently optimal physiological conditions. These innovative capabilities will allow researchers to pursue cutting-edge research topics that are not addressable with existing technology.

The core element of the SmartSlide Micro-Incubation System is the compact, sterile and disposable SmartSlide-6 Micro-Incubator which is designed to maintain cells at specific physiological conditions for prolonged cell or tissue imaging. The SmartSlide-6 Micro-Incubator allows for programmable fluidics exchanging, enabling the delivery of up to six nutrient media and gas into each of its six individual wells in both intermittent and continuous perfusion modes.

WaferGen has developed a family of SmartSlide Micro-Incubation System products built upon the SmartSlide-6 Micro-Incubator that offers cell biology and stem cell researchers varying levels of control over specific environmental conditions such as nutrient flow, temperature, humidity, gas and pH. Each of these SmartSlide Micro-Incubation System products incorporates easy-to-use graphical interface software that allows for complete walk-away automation. The SmartSlide Micro-Incubation System family of products consists of four currently marketed products: SmartSlide 50 Micro-Incubation System(TM), SmartSlide 100 Micro-Incubation System(TM), SmartSlide 150 Micro-Incubation System(TM), and SmartSlide 200 Micro-Incubation System(TM).

Since the launch of its SmartSlide Micro-Incubation System in late 2006, WaferGen has seen a positive response from many leading research institutions and organizations. The company's current SmartSlide(TM) Micro-Incubation System customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, the National Institutes of Health (NIH), and several leading pharmaceutical companies.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide(TM), which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide(TM) customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, and the National Institutes of Health (NIH).

To learn more about WaferGen, please visit the company's web site at http://www.wafergen.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements relating to the expected benefits to the company in overseas markets of the new distribution agreement, and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For such statements, the company claims the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2007. Investors and security holders are urged to read this document free of charge on the SEC's web site at http://www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

Vida Communication (On behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7402

sdiaz@vidacommunication.com tbrons@vidacommunication.com


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. Monsanto Company Signs Share Subscription Agreement With Devgen
10. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
11. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Morf Media ... compliance training platform on mobile devices, today released a new interactive Food ... Medical Devices. The course is essential for owners or operators of places of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech + ... conferences, will take place on June 7-8, 2016, at the New York Academy of ... incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout a ...
(Date:5/2/2016)... -- Q BioMed Inc. (QBIO), a biotechnology ... Inc. will be attending the Association for Research in ... 1-5, 2016 in Seattle Washington . ... and research partners. The meeting provides organizations the opportunity ... opportunities for the MAN-01 program for treatment of glaucoma. ...
(Date:4/29/2016)... Irvine, CA (PRWEB) , ... April 29, 2016 ... ... research leader in personalized pain medicine, is excited to announce the launch of ... to supporting public health studies, volunteerism, and education to promote the use of ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):